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ABSTRACT Pemphigus vulgaris (PV) is a life-threatening, autoimmune blister-
ing disease affecting the skin and mucous membranes, exerting a detrimental 
effect on the quality of life (QOL). Our aim was to evaluate the psychological 
status and QOL of patients with PV and investigate Interleukin-6 (IL-6) as a pos-
sible contributor to the pathogenesis of pemphigus and associated depression. 
The study included 22 patients with PV, 21 patients with depression, and 20 
normal controls. All the 63 participants were subjected to assessment of their 
QOL, psychiatric profile, as well as estimation of serum level of IL-6. All (100%) of 
the included patients with PV had a negative effect on their QOL, which was sig-
nificant compared with controls (P<0.001). Among patients with PV, 13 patients 
(59.1%) had depression. IL-6 was non-significantly elevated in the pemphigus 
group when compared with the controls (P=0.057). QOL was significantly worse 
in the depressed pemphigus subgroup compared with the non-depressed pem-
phigus subgroup (P=0.006 and <0.001) respectively. However, IL-6 was non-sig-
nificantly elevated in the depressed pemphigus subgroup compared with the 
non-depressed pemphigus subgroup (P=0.095). A marked deterioration in the 
QOL was observed in patients with pemphigus. More than 50%, but not all, of 
patients with pemphigus had depression. IL-6 was non-significantly elevated in 
patients with pemphigus.
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INTRODUCTION
Pemphigus vulgaris (PV) is a chronic disabling dis-
order, characterized by painful oral erosions and flac-
cid skin blisters. It occurs due to IgG autoantibodies 
against desmoglein 3 (Dsg3), leading to acantholysis 
of keratinocytes and blister formation (1). Presenta-
tion by painful oral and cutaneous erosions, difficulty 
in eating, in addition to the disfiguring nature of the 
disease and avoidance of social interaction, all exert 
a negative effect on the patients quality of life (QOL). 
Furthermore, the need for long-term hospitalization, 
the financial burden, and side-effects of treatment 
can ultimately lead to different psychiatric disorders 
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including profound depression associated with sui-
cidal ideation (2).
Previous studies have investigated the role of dif-
ferent inflammatory cytokines such as interleukin 
(IL)-1, IL-2, IL-6, and TNF-alpha in PV pathogenesis (3). 
The same cytokines were suggested to precede de-
pressive symptoms, providing support for a pathway 
from inflammation to depression. IL-6 was found to 
be elevated in sera and blister fluid obtained from pa-
tients with PV and it was suggested it plays a role in 
acantholysis. During remission with immunosuppres-
sive treatment, a decreased level of IL-6 was detected 
in PV (4). Adults with depression similarly showed 
raised inflammatory markers, including IL-6 (5).
This study aimed at evaluating the psychological 
status and the QOL among patients with PV, in addi-
tion to investigating IL-6 as a possible contributor to 
the pathogenesis of pemphigus and the associated 
depression.
PATIENTS AND METHODS 
This study was conducted at the Dermatology 
Outpatient Clinic and has been approved by the Der-
matology Research Ethical Committee (Derma REC) 
with informed consent signed by all participants.
Twenty-two patients with PV were recruited; di-
agnosis was based on both clinical and histopatho-
logical examination. Inclusion criteria included: fresh 
cases of PV (not previously treated) and patients in 
exacerbation being off any treatment for at least 2 
weeks. Patients with diabetes mellitus, neurological 
disease, autoimmune diseases, or any malignancies 
were excluded as there is growing evidence that IL-6 
play a role in such diseases (6,7).
For all patients, a full detailed history was taken 
and complete general examination was performed 
with emphasis on the general condition and exclud-
ing manifestations of internal malignancy. Lymph-
adenopathy, hepatosplenomegaly, jaundice, and 
pelvi-abdominal masses were ruled out. 
Dermatological examination was performed at 
the time of presentation by two fixed investigators to 
determine the type of PV as mucosal (MPV) or mu-
cocutaneous (MCPV). The mucosal type was defined 
as that with limited skin involvement (<6 erosions 
or blisters and each <5 cm in diameter), whereas 
the mucocutaneous type was defined as that with 
extensive skin involvement (>6 erosions or blisters, 
>5 cm in diameter) (8). The severity of the included 
cases was calculated using the pemphigus area and 
activity score (PAAS) (9). A final grading of being free, 
mild, moderate, or severe was calculated accordingly 
(Table 1). 
Twenty-one patients with depression without a 
known autoimmune or dermatological disease were 
recruited from the Psychiatry Outpatient Clinic, Kasr 
Table 1. Pemphigus area and activity score (PAAS) for cutaneous and mucus membrane lesions (9)
Clinical markers (Body  
lesions)
Clinical scores
0 1 2 3 4 5 6
A: Activity
– No. of new blisters/day













































Head score (H) = [(a + b + c) × score of area] ×0.1.
Trunk score (T) = [(a + b + c) × sore of area] ×0.3.
Upper limbs score (UL) = [(a + b + c) × score of area] ×0.2.
Lower limbs core (LL) = [(a + b + c) × score of area] ×0.4.
Total cutaneous score + H + T + UL + LL.
*Grade; free: 0, mild: 1-36, moderate: 37-72, severe: 73-108.
Mucus membrane score (MM) = area score + severity Score;
*Grade; free: 0; mild: 1, 2; moderate: 3, 4; severe: 5, 6.
Total score = cutaneous score + MM score.
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Table 2. Scoring and Interpretation of Dermatology Life Quality Index (DLQI) (12)
10 questions, each question answer is scored as follows
Very much scored 3
A lot scored 2
A little scored 1
Not at all scored 0
Not relevant scored 0
Question 6: unanswered scored 0
Question 7: "prevented work or studying" scored 3
The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0 and 
interpreted as follows
0-1 No effect at all on patient’s life.
2-5 Small effect on patient’s life.
6-10 Moderate effect on patient’s life
11-20 Very large effect on patient’s life
21-30 Extremely large effect on patient’s life
DLQI: Dermatology Life Quality Index
Al Aini Hospital. In addition, twenty normal individu-
als with no known systemic, psychological, or derma-
tological diseases were included as controls. 
Assessment of QOL, prevalence of  
depression and the level of IL-6
All participants were subjected to assessment of 
their psychiatric profile using Hamilton Depression 
Rating Scale (HDRS) (10) and Beck depression inven-
tory (BDI) (11) (Arabic Version). Additionally, patient 
QOL was assessed via the Dermatology Life Quality 
Index (DLQI) as illustrated in Table 2 and B-Quality of 
life questionnaire QOL (12) which consists of 30 ques-
tions to assess somatic problems, thinking problems, 
mood problems, social stressor, economic problems, 
and special problems. The test was translated and 
standardized by Akram Kamal to be used in an Arabic 
version.
Three mL venous blood samples were collected 
by venipuncture from all participants. Blood was 
subjected to clot. Subsequently, each blood sample 
was centrifuged to separate serum. Serum samples 
were kept at -20 oC in Eppendorf tubes until being 
processed for IL-6 estimation. Serum IL-6 was deter-
mined for both patients and controls using the ELISA 
kit (Ani Biotech Orgenium Laboratories Business Unit 
Tiilitie 3FIN-07120 Vantaa-FINLAND).
Statistical analysis
Data were statistically described in terms of mean 
± standard deviation (±SD), median and range, or fre-
quencies (number of cases) and percentages when 
appropriate. Comparison of numerical variables be-
tween the study groups was done using the Mann-
Whitney U test for independent samples. For compar-
ing categorical data, the Chi-square (х2) test was per-
formed. Exact test was used instead when the expect-
ed frequency was less than 5. Correlation between 
various variables was assessed using Spearman rank 
correlation equation for non-normal variables/non-
linear monotonic relation. Multivariate analysis was 
used to test for the preferential effect of the selected 
important independent variable(s) on IL-6 levels in PV 
cases. P values less than 0.05 were considered statisti-
cally significant. All statistical calculations were per-
formed using SPSS the computer program (Statistical 
Package for the Social Science; SPSS Inc., Chicago, IL, 
USA), release 15 for Microsoft Windows (2006).
RESULTS
The present study included 22 patients with PV, 5 
men (22.7%) and 17 women (77.3%). Their age ranged 
from 17-75 years with a mean of 43.14 years ± SD 
12.63. The duration of disease ranged from 1 month 
– 12 years with a mean of 2.24 years ± SD 34.46. 
Figure 1. Serum Interleukin-6 in the three study groups.
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Fourteen (64%) of the patients were recurrent cases 
and 8 (36%) were newly diagnosed. Twelve patients 
(54.5%) presented with mucocutaneous lesions, while 
ten patients (45.5%) presented with mucosal lesions. 
None of the patients had cutaneous lesions only (0%). 
PAAS ranged from 3.5 to 38.6 in mucocutaneous le-
sions with mean 12.64 ± SD 11.49, and this was trans-
lated into (8.3%) moderate and (91.7%) mild cases and 
ranged from 2 to 3 in mucosal lesions with mean 2.6 ± 
SD 0.516, with (60%) moderate and (40%) mild cases.
Twenty one patients belonging to the depression 
group were also included as controls, eight of whom 
were men (38.1%) and 13 women (61.9%), with age 
ranging between 23-62 years with a mean of 40.81 
years ± SD 10.93. The duration of their depression 
ranged from 6 months to 5 years with a mean of 1.9 
years ± SD 16.06. Sixteen (76%) of the patients were 
in remission and exacerbation, and 5 (24%) were 
newly diagnosed. Regarding the healthy controls, 
five were men (25%) and 15 were women (75%), with 
age ranging from 22 to 57 years with a mean of 33.15 
years ± SD 9.85. Regarding smoking, 2/22 (9.1%) pa-
tients with PV, 7/21(33.3%) depressed patients, and 
2/20 (10.0 %) normal controls were smokers (P>0.05). 
The prevalence and degree of depression among the 
PV group, depression group, as well as in the control 
group are shown in Table 3.
All (100%) included PV had a negative effect on 
their DLQI. Eleven patients (50%) had extremely large 
effect on their life, and 11 patients (50%) had very 
large effect on their life. As regards the QOL index, 
the worst score was recorded among the PV group 
(P<0.001) with a mean of 15.318 ± SD 4.79 and de-
pression group (P<0.001) with a mean 18.095 ±SD 
4.43. There was also significant difference between 
pemphigus and depression groups (P=0.026). The 
best score was recorded among normal controls, with 
a mean of 32.65±SD 2.059, with a significant differ-
ence in comparison to other groups (P<0.001). 
There was a significant difference in IL-6 between 
the three study groups (P=0.046) (Figure 1). IL-6 level 
was highest in the depression group (Range 2-356, 
mean±SD 59.88±111.087) and lowest in the normal 
controls (Range 1-3.60, mean±SD 1.99±0.804). IL-
6 was non-significantly elevated in the pemphigus 
group (Range 1-224, mean±SD 48.02±70.819), when 
compared with the control group (P=0.056) and there 
was no significant difference when compared with 
the depression group (P=0.125). There was significant 
difference in IL-6 between the depression group and 
control (P=0.039).
Dermatology life quality index was significantly 
worse in the depressed pemphigus subgroup (N=13) 
(mean 23.08 ± SD 3.52), when compared with the 
non-depressed pemphigus subgroup (N=9) (mean 
16.78 ± SD 5.14) (P=0.006). QOL questionnaire results 
were significantly worse in the depressed pemphigus 
subgroup (N=13) (mean 12.31 ± SD 2.59) when com-
pared with the non-depressed pemphigus subgroup 
(N=9) (mean 19.67 ± SD 3.77) (P<0.001). IL-6 was 




No Count 9 0 14 9
% within Group 40.9% 0.0% 70% 20.9%






Count 22 21 20 43





Depression Count 13 21 6
P<0.001*
% within Group 59.1% 100% 30%
Mild Count 3 0 6
% within Group 13.6% 0.0% 30%
Moderate Count 5 12 0
% within Group 22.7% 57.1% 0%
Severe Count 5 9 0
% within Group 22.7% 42.9% 0%
* P value <0.05 is statistically significant
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non-significantly elevated in the depressed pemphi-
gus subgroup (N=13) (mean 57.15 ± SD 72.908) when 
compared with the non-depressed pemphigus sub-
group (N=9) (mean 34.83 ± SD 69.719) (P=0.095).
The degree of depression in the pemphigus 
group showed a significant positive correlation with 
cutaneous score (P<0.001), mucous membrane 
score (P=0.002), and total PAAS (P<0.001) and a sig-
nificant negative correlation with the disease dura-
tion (P=0.019). Similarly, the DLQI in the pemphigus 
group showed a significant negative correlation with 
disease duration (P=0.022) and the DLQI showed a 
significant positive correlation with degree of depres-
sion (P=0.003), cutaneous score (P=0.006), mucous 
membrane score (P=0.019), and total PAAS (P=0.015). 
IL-6 showed a significant correlation with cutaneous 
score (P=0.030).
In the depression group, a statistically significant 
correlation was found between IL-6 and disease dura-
tion (P=0.015), in addition to a significant correlation 
between degree of depression and QOL (P<0.001). 
No significant correlations were otherwise detected 
between any of the assessed parameters.
DISCUSSION
The current study adds PV to the long list of der-
matological diseases that could be influenced by 
or influence the QOL of the affected patient. To our 
knowledge, there are no previous studies that investi-
gated the relation between the QOL, depression, and 
cytokine level in patients with PV. Our assumption 
that pemphigus is a psychocutaneous interrelated 
disease is based on the deteriorated DLQI in the in-
cluded 22 patients with pemphigus, where 50% had 
an extremely large effect on their life and 50% showed 
a very large effect on their life. Furthermore, the QOL 
questionnaire results were significantly worse in the 
pemphigus group compared with both the depres-
sion group and the control group. This finding was 
also reported in previous studies (13,14).
An important finding in our study was more im-
pairment of QOL in patients with recent onset of the 
disease, i.e. DLQI in newly diagnosed patients with 
pemphigus compared with DLQI for recurrent cases. 
Although QOL is expected to get worse over time, 
adaptation of the patients to their condition may be 
responsible for a relatively poorer QOL in the early 
stages of PV in our patients. Over a certain period of 
time, controlling the symptoms, learning about differ-
ent aspects of the disease, and coping more efficient-
ly with the disease and therapies may significantly 
improve the patients’ health status. This finding was 
similar to another report (15).
In our study, depression was detected in most 
included patients with pemphigus (59.1%), and this 
finding has been previously reported (15,16). More-
over, QOL in the depressed pemphigus group was 
significantly deteriorated compared with the non-
depressed pemphigus group according to both the 
DLQI and QOL questionnaires. A similar finding was 
found by Arbabi et al. (17), but whether the depres-
sion was a key factor which lowered their QOL scores 
or the other way around is a question that remains to 
be answered. Either way, it raised a red flag about the 
importance of a good psychiatric analysis for patients 
with pemphigus to be able to evaluate their psychiat-
ric illness at an early stage.
On the other hand, 40.9% of the included patients 
with pemphigus in our study were not depressed, 
further confirming the need for proper psychiatric 
assessment, as it indicated that not all patients with 
pemphigus need antidepressant medications. 
There was significant correlation between PAAS 
and degree of depression. The correlation between 
PAAS and DLQI was also significant. This can go in one 
of two directions; either clinical impairment leads to 
QOL deterioration, which is quite logical, or QOL dete-
rioration leads to clinical impairment. IL-6 was inves-
tigated as a possible culprit for this connection, and 
to our knowledge this was the first study that tried to 
find a link between IL-6, depression, and PV.
The pathogenesis of pemphigus disease is fre-
quently characterized by pro-inflammatory cytokine 
production such as TNF-α, IL-1, or IL-6 as strong players 
involved in acantholysis (18). Evidence for the role of 
raised inflammatory markers in depression has been 
building over the last 20 years. In the current study, 
there was a significant difference in IL-6 between 
the three studied groups and was higher in the de-
pression group and higher in the pemphigus group 
than normal controls, which might be explained by 
the role of IL-6 as one of inflammatory cytokines in 
pathogenesis of depression and pemphigus (18). IL-
6 was non-significantly elevated in the pemphigus 
group when compared with the control group, which 
might be explained by small sample size and the role 
of cytokines other than IL-6 incriminated in pemphi-
gus pathogenesis. 
In our study, there was an absence of a significant 
correlation between IL-6 on one hand and PASS as 
well as DLQI on the other hand. The multifactorial na-
ture of the studied disease offers an explanation to 
the absence of such correlation. However, Narbutt et 
al. (4) showed that IL-6 serum concentration was sig-
nificantly higher in the patients presenting the active 
stage of PV when compared with the control group.
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CONCLUSION
We recommend taking QOL changes into account 
during the initial clinical assessment of patients with 
pemphigus. Physicians must be aware of the presen-
tation of depression and anxiety among such patients. 
Proper management of these symptoms can improve 
their QOL considerably. Antidepressant drugs should 
not be obligatory in all pemphigus cases, but only in 
selected ones. Further studies are needed to confirm 
the role of IL-6 in pemphigus pathogenesis.
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